sb 203580 has been researched along with andrographolide in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (andrographolide) | Trials (andrographolide) | Recent Studies (post-2010) (andrographolide) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 923 | 9 | 736 |
| Protein | Taxonomy | sb 203580 (IC50) | andrographolide (IC50) |
|---|---|---|---|
| Bile acid receptor | Homo sapiens (human) | 9.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiou, WF; Tsai, HR; Tsai, WJ; Yang, LM | 1 |
1 other study(ies) available for sb 203580 and andrographolide
| Article | Year |
|---|---|
Andrographolide acts through inhibition of ERK1/2 and Akt phosphorylation to suppress chemotactic migration.
Topics: Androstadienes; Animals; Anthracenes; Cell Line; Cell Movement; Cell Survival; Chemokine CCL4; Chemotaxis; Chromones; Complement C5a; Diterpenes; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flavonoids; Imidazoles; JNK Mitogen-Activated Protein Kinases; Macrophage Inflammatory Proteins; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Morpholines; p38 Mitogen-Activated Protein Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Wortmannin | 2004 |